BioAge Labs (NASDAQ:BIOA) Shares Gap Up – Should You Buy?

BioAge Labs, Inc. (NASDAQ:BIOA)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $19.63, but opened at $21.40. BioAge Labs shares last traded at $20.68, with a volume of 829,123 shares trading hands.

Analyst Upgrades and Downgrades

BIOA has been the subject of a number of analyst reports. Wall Street Zen upgraded shares of BioAge Labs from a “sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Piper Sandler started coverage on BioAge Labs in a research report on Tuesday, January 27th. They set an “overweight” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research note on Tuesday, January 27th. Citigroup increased their price target on shares of BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, Morgan Stanley set a $23.00 price target on shares of BioAge Labs in a research report on Wednesday, February 4th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $19.00.

BioAge Labs Price Performance

The stock’s 50-day moving average is $16.92 and its 200 day moving average is $10.05. The stock has a market cap of $708.14 million, a price-to-earnings ratio of -13.01 and a beta of 1.42.

Insiders Place Their Bets

In other BioAge Labs news, CFO Dov A. Md Goldstein sold 27,000 shares of the business’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total transaction of $531,900.00. Following the sale, the chief financial officer directly owned 22,408 shares in the company, valued at approximately $441,437.60. The trade was a 54.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Paul D. Rubin sold 68,897 shares of the company’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $10.19, for a total transaction of $702,060.43. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 354,437 shares of company stock worth $5,813,228. 20.82% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. CWM LLC boosted its position in shares of BioAge Labs by 39.9% in the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after buying an additional 1,053 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in BioAge Labs by 24.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,808 shares of the company’s stock worth $196,000 after acquiring an additional 2,917 shares during the last quarter. Barclays PLC lifted its holdings in shares of BioAge Labs by 9.3% in the fourth quarter. Barclays PLC now owns 37,780 shares of the company’s stock valued at $500,000 after purchasing an additional 3,222 shares in the last quarter. Bank of America Corp DE grew its position in shares of BioAge Labs by 46.3% in the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock valued at $65,000 after purchasing an additional 3,517 shares during the last quarter. Finally, Vontobel Holding Ltd. increased its stake in shares of BioAge Labs by 36.4% during the 3rd quarter. Vontobel Holding Ltd. now owns 15,000 shares of the company’s stock worth $88,000 after purchasing an additional 4,000 shares in the last quarter.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.